1. 1.Hosseinzadeh A, Baneshi MR, Sedighi B, Kermanchi J, Haghdoost AA. Estimation of Parkinson's Disease Prevalence and Its Geographical Variation in Iran. J Mazandaran Univ Med Sci. 2021;31(200):113-124.

2. Del Tredici K, Rüb U, De Vos RA, Bohl JR, Braak H. Where does parkinson disease pathology begin in the brain? J Neuropathol Exp Neurol. 2002;61(5):413-426. [DOI:10.1093/jnen/61.5.413] [PMID]

3. Castelli V, d'Angelo M, Lombardi F, Alfonsetti M, Antonosante A, Catanesi M, et al. Effects of the probiotic formulation SLAB51 in in vitro and in vivo Parkinson's disease models. Aging. 2020;12(5):4641-4659. [DOI:10.18632/aging.102927] [PMID] []

4. Ueki A, Otsuka M. Life style risks of Parkinson's disease: association between decreased water intake and constipation. J Neurol. 2004;251:vii18-vii23. [DOI:10.1007/s00415-004-1706-3] [PMID]

5. Khosravi F, Hojati V, Entezari M, Hashemi M. Evaluation of neuroprotective effects of cobalamin (vitamin B12) in Parkinson's disease-Investigation of molecular mechanisms. Med Sci J of Islamic Azad Uni-Tehran 2021;33(4):381-392.

6. Surwase SN, Jadhav JP. Bioconversion of L-tyrosine to L-DOPA by a novel bacterium Bacillus sp. JPJ. J Amino Acids. 2011;41(2):495-506. [DOI:10.1007/s00726-010-0768-z] [PMID]

7. Browne HP, Forster SC, Anonye BO, Kumar N, Neville BA, Stares MD, et al. Culturing of 'unculturable'human microbiota reveals novel taxa and extensive sporulation. Nature. 2016;533(7604):543-546. [DOI:10.1038/nature17645] [PMID] []

8. Çamcı G, Oğuz S. Association between Parkinson's disease and Helicobacter pylori. J Clin Neurol. 2016;12(2):147-150. [DOI:10.3988/jcn.2016.12.2.147] [PMID] []

9. Scheperjans F, Aho V, Pereira PA, Koskinen K, Paulin L, Pekkonen E, et al. Gut microbiota are related to Parkinson's disease and clinical phenotype. J Mov Disord. 2015;30(3):350-358. [DOI:10.1002/mds.26069] [PMID]

10. Forsyth CB, Shannon KM, Kordower JH, Voigt RM, Shaikh M, Jaglin JA, et al. Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson's disease. PloS one. 2011;6(12):e28032. [DOI:10.1371/journal.pone.0028032] [PMID] []

11. Keshavarzian A, Green SJ, Engen PA, Voigt RM, Naqib A, Forsyth CB, et al. Colonic bacterial composition in Parkinson's disease. Mov Disord. 2015;30(10):1351-1360. [DOI:10.1002/mds.26307] [PMID]

12. Derkinderen P, Shannon KM, Brundin P. Gut feelings about smoking and coffee in Parkinson's disease. Mov Disord. 2014;29(8):976-979. [DOI:10.1002/mds.25882] [PMID] []

13. Khandestan K, Pakpour B, Tajabadi Ebrahimi M. Effect of Lactobacillus paracasei probiotic in Parkinson's male rats. J Gorgan Univ Med Sci. 2020;22(3):65-72.

14. Kosiewicz MM, Zirnheld AL, Alard P. Gut microbiota, immunity, and disease: a complex relationship. Front microbiol. 2011;2:180. [DOI:10.3389/fmicb.2011.00180] [PMID] []

15. Lotan D, Cunningham M, Joel D. Antibiotic treatment attenuates behavioral and neurochemical changes induced by exposure of rats to group a streptococcal antigen. PLoS One. 2014;9(6):e101257. [DOI:10.1371/journal.pone.0101257] [PMID] []

16. Investigators NN-P. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. J Neurol. 2006;66(5):664-671. [DOI:10.1212/01.wnl.0000201252.57661.e1] [PMID]

17. Yang T, Santisteban MM, Rodriguez V, Li E, Ahmari N, Carvajal JM, et al. Gut dysbiosis is linked to hypertension. J Hypertens. 2015;65(6):1331-1340. [DOI:10.1161/HYPERTENSIONAHA.115.05315] [PMID] []

18. Tallarida CS, Corley G, Kovalevich J, Yen W, Langford D, Rawls SM. Ceftriaxone attenuates locomotor activity induced by acute and repeated cocaine exposure in mice. Neurosci Lett. 2013;556:155-159. [DOI:10.1016/j.neulet.2013.09.072] [PMID] []

19. Davey K, Cotter P, O'sullivan O, Crispie F, Dinan T, Cryan J, et al. Antipsychotics and the gut microbiome: olanzapine-induced metabolic dysfunction is attenuated by antibiotic administration in the rat. Transl Psychiatry. 2013;3(10):e309-e309. [DOI:10.1038/tp.2013.83] [PMID] []

20. Bravo JA, Forsythe P, Chew MV, Escaravage E, Savignac HM, Dinan TG, et al. Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve. PNAS. 2011;108(38):16050-16055. [DOI:10.1073/pnas.1102999108] [PMID] []

21. Marselle MR, Hartig T, Cox DT, De Bell S, Knapp S, Lindley S, et al. Pathways linking biodiversity to human health: A conceptual framework. Environ Int. 2021;150:106420. [DOI:10.1016/j.envint.2021.106420] [PMID]

22. Gazerani P. Probiotics for Parkinson's disease. Int J Mol Sci. 2019;20(17):4121. [DOI:10.3390/ijms20174121] [PMID] []

23. Hwang O. Role of oxidative stress in Parkinson's disease. Exp Neurobiol. 2013;22(1):11. [DOI:10.5607/en.2013.22.1.11] [PMID] []

24. Miyake Y, Fukushima W, Tanaka K, Sasaki S, Kiyohara C, Tsuboi Y, et al. Dietary intake of antioxidant vitamins and risk of Parkinson's disease: a case-control study in Japan. Eur J Neurol. 2011;18(1):106-113. [DOI:10.1111/j.1468-1331.2010.03088.x] [PMID]

25. Smith MP, Fletcher-Turner A, Yurek DM, Cass WA. Calcitriol protection against dopamine loss induced by intracerebroventricular administration of 6-hydroxydopamine. Neurochem Res. 2006;31:533-539. [DOI:10.1007/s11064-006-9048-4] [PMID]

26. Murakami K, Miyake Y, Sasaki S, Tanaka K, Fukushima W, Kiyohara C, et al. Dietary intake of folate, vitamin B6, vitamin B12 and riboflavin and risk of Parkinson's disease: a case-control study in Japan. Br J Nutr. 2010;104(5):757-764. [DOI:10.1017/S0007114510001005] [PMID]

27. Yoshii K, Hosomi K, Sawane K, Kunisawa J. Metabolism of dietary and microbial vitamin B family in the regulation of host immunity. Front nutr. 2019;6:48. [DOI:10.3389/fnut.2019.00048] [PMID] []

28. Pompei A, Cordisco L, Amaretti A, Zanoni S, Matteuzzi D, Rossi M. Folate production by bifidobacteria as a potential probiotic property. Appl Environ Microbiol. 2007;73(1):179-185. [DOI:10.1128/AEM.01763-06] [PMID] []

29. Aas J, Gessert CE, Bakken JS. Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. J Infect Dis. 2003;36(5):580-585. [DOI:10.1086/367657] [PMID]

30. Borody TJ, Khoruts A. Fecal microbiota transplantation and emerging applications. Nat Rev Gastroenterol Hepatol. 2012;9(2):88-96. [DOI:10.1038/nrgastro.2011.244] [PMID]

31. Collins SM, Surette M, Bercik P. The interplay between the intestinal microbiota and the brain. Nat Rev Microbiol. 2012;10(11):735-742. [DOI:10.1038/nrmicro2876] [PMID]

32. Jenner P, Olanow CW. The pathogenesis of cell death in Parkinson's disease. J Neurol. 2006;66(10 suppl 4):S24-S36. [DOI:10.1212/WNL.66.10_suppl_4.S24] [PMID]

33. Arai H, Furuya T, Mizuno Y, Mochizuki H. Inflammation and infection in Parkinsons disease. Histol Histopathol. 2006.

34. Beaman BL, Canfield D, Anderson J, Pate B, Calne D. Site-specific invasion of the basal ganglia by Nocardia asteroides GUH-2. Med Microbiol Immunol. 2000;188:161-168. [DOI:10.1007/s004309900030] [PMID]

35. Bu X-L, Wang X, Xiang Y, Shen L-L, Wang Q-H, Liu Y-H, et al. The association between infectious burden and Parkinson's disease: a case-control study. Park Relat Disord. 2015;21(8):877-881. [DOI:10.1016/j.parkreldis.2015.05.015] [PMID]

36. Matsui H, Ito H, Taniguchi Y, Inoue H, Takeda S, Takahashi R. Proteasome inhibition in medaka brain induces the features of Parkinson's disease. J Neurochem. 2010;115(1):178-187. [DOI:10.1111/j.1471-4159.2010.06918.x] [PMID]

37. Pablo J, Banack S, Cox P, Johnson T, Papapetropoulos S, Bradley W, et al. Cyanobacterial neurotoxin BMAA in ALS and Alzheimer's disease. Acta Neurol Scand. 2009;120(4):216-225. [DOI:10.1111/j.1600-0404.2008.01150.x] [PMID]

38. Scheperjans F, Pekkonen E, Kaakkola S, Auvinen P. Linking smoking, coffee, urate, and Parkinson's disease-a role for gut microbiota? J Parkinsons Dis. 2015;5(2):255-262. [DOI:10.3233/JPD-150557] [PMID]

39. Xu X, Fu Z, Le W. Exercise and Parkinson's disease. Int Rev Neurobiol. 2019;147:45-74. [DOI:10.1016/bs.irn.2019.06.003] [PMID]

40. Wall R, Cryan JF, Ross RP, Fitzgerald GF, Dinan TG, Stanton C. Bacterial neuroactive compounds produced by psychobiotics. J Endocrinol. 2014:221-239. [DOI:10.1007/978-1-4939-0897-4_10] [PMID]